Anonymousabout 3 hours ago
Personalized mRNA cancer vaccines are producing striking early clinical data — a 49% reduction in melanoma recurrence and six-year survival signals in pancreatic cancer — even as the field endures unprecedented political headwinds including nearly $500 million in canceled federal contracts and an anti-mRNA posture from senior U.S. health officials. With more than 120 clinical trials underway, four now in Phase III, and regulatory submissions anticipated in 2026, the technology faces a critical test: whether promising Phase I/II results can survive the historically brutal attrition rate of late-stage oncology trials, and whether personalized manufacturing can scale to serve patients beyond wealthy health systems.